Proposal to list orthopaedic implants and associated products supplied by Orthomed NZ Limited
What we’re proposing
PHARMAC is seeking feedback on a proposal to list a range of Orthopaedic Implants and Associated Products supplied by Orthomed NZ Limited (“Orthomed”) in Part III of Section H of the Pharmaceutical Schedule from 1 April 2018.
Consultation closes at 4pm on Friday 2 March 2018 and feedback can be emailed to maree.hodgson@pharmac.govt.nz.
What would the effect be?
From 1 April 2018, Orthomed’s range of Orthopaedic Implants and Associated Products would be listed under a proposed national agreement that all DHBs may purchase under, subject to consultation and approval by PHARMAC’s Board or delegate (“Agreement”).
DHBs would be able to continue to procure other suppliers’ ranges of Orthopaedic Implants and Associated Products, as the Agreement would not be for sole supply.
Who we think will be interested
- Suppliers and Wholesalers
- DHB Staff
- Orthopaedic Surgeons
- Theatre and Sterile Services personnel
- Procurement and supply chain personnel
About the orthopaedic implants and associated products
The Orthopaedic implants under this agreement are used to treat bone related injury or disease through surgical intervention. The Associated Products relate to the instruments or products required for preparation and/or adherence at the implant site, or physical manipulation of the implants required when undertaking the surgery.
Why we’re proposing this
The purpose of the RFP was to secure national contracts for DHB hospitals to purchase off, establish the orthopaedic category on the Pharmaceutical Schedule and, where possible, secure some immediate savings for DHBs.
Orthomed responded to the RFP and their proposal was in line with the scope of the RFP. PHARMAC has been working with a range of suppliers to seek provisional agreements and this proposal is the latest to arise from that process. Further consultations in this category are expected over the next few months.
Details about our proposal
PHARMAC has entered into a provisional Agreement with Orthomed for the supply of Orthopaedic Implants and Associated Products to DHBs that would result in listing 139 products on the Pharmaceutical Schedule from 1 April 2018.
Manufacturers and ranges included in the Agreement are:
|
Manufacturer |
Brands |
|---|---|
|
Adler Ortho |
FIXA Ti-por Modular Sleeve Polymax Revision Head |
|
Evolutis |
Ceramic Head Metal Head Stemsys |
Pricing has not been included in this consultation but has been made available to Procurement Departments at DHBs.
DHBs would be able to continue to choose which Orthopaedic Implants and Associated Products they procure.
The Agreement includes terms for training and education services to be provided by Orthomed to DHB personnel on appropriate use of its Orthopaedic Implants and Associated Products, which is to be provided at times as agreed with individual DHBs.
To provide feedback
Send an email to maree.hodgson@pharmac.govt.nz by 4pm, Friday 2 March 2018.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.